<ѻýҕl>Sickle Cell Disease Patients Miss Out on Decades of Lifeѻýҕl> What effects might emerging therapies have on real-world survival? Mar 17, 2023
<ѻýҕl>FDA Panel Endorses New First-Line Lymphoma Regimenѻýҕl> POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
<ѻýҕl>FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimenѻýҕl> Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
<ѻýҕl>Full-Dose Anticoagulation Again Favored for COVID Admissionsѻýҕl> Despite failures, FREEDOM trial supports mortality advantage in general ward use Mar 07, 2023
<ѻýҕl>Cases of Breast Implant-Associated Lymphoma Continue to Accumulateѻýҕl> More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
<ѻýҕl>'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advancesѻýҕl> News, features, and commentary about cancer-related issues Mar 03, 2023
<ѻýҕl>Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoeѻýҕl> News, features, and commentary about cancer-related issues Feb 24, 2023
<ѻýҕl>Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Yearsѻýҕl> Model predicts valoctocogene roxaparvovec could maintain mild hemophilia levels for 5 years Feb 23, 2023
<ѻýҕl>Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALLѻýҕl> Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
<ѻýҕl>The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Marketѻýҕl> New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
<ѻýҕl>Novel 'Off the Shelf' CAR-T Product Shows Promise in Myelomaѻýҕl> Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
<ѻýҕl>New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia Aѻýҕl> Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
<ѻýҕl>Inflammatory VEXAS Syndrome May Not Be So Uncommonѻýҕl> Is new disease being missed by physicians? Jan 24, 2023
<ѻýҕl>Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complicationѻýҕl> Observational study provides suggestive evidence Jan 17, 2023
<ѻýҕl>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCTѻýҕl> Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<ѻýҕl>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignanciesѻýҕl> Most patients had no recurrence of their original intolerance event Jan 10, 2023
<ѻýҕl>Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphomaѻýҕl> However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
<ѻýҕl>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematologyѻýҕl> After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<ѻýҕl>Early Win for Gene Therapy in Rare Form of SCIDѻýҕl> 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
<ѻýҕl>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin'sѻýҕl> 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
<ѻýҕl>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCTѻýҕl> Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<ѻýҕl>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLLѻýҕl> Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<ѻýҕl>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuriaѻýҕl> Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
<ѻýҕl>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALLѻýҕl> Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<ѻýҕl>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimodѻýҕl> Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
<ѻýҕl>Black Patients Less Likely to Get Advanced Treatments for PEѻýҕl> Also less likely for patients on Medicare and Medicaid Dec 12, 2022
<ѻýҕl>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCTѻýҕl> Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<ѻýҕl>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myelomaѻýҕl> Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<ѻýҕl>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphomaѻýҕl> Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
<ѻýҕl>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻýҕl> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻýҕl>New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemiaѻýҕl> Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
<ѻýҕl>FDA OKs First Gene Therapy for Hemophilia Bѻýҕl> Hemgenix reduced rate of annual bleeds, eliminated need for factor IX prophylaxis therapy Nov 22, 2022
<ѻýҕl>Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myelomaѻýҕl> No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
<ѻýҕl>Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standardѻýҕl> Europe and other countries have already followed suit Nov 01, 2022
<ѻýҕl>FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamabѻýҕl> Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
<ѻýҕl>Transplant With Orca-T Reduced GVHD in Hematologic Malignanciesѻýҕl> Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<ѻýҕl>ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphomaѻýҕl> Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
<ѻýҕl>Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myelomaѻýҕl> Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
<ѻýҕl>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?ѻýҕl> Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<ѻýҕl>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDSѻýҕl> About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022